Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc. Common Stock
Your view on PLYX
Overview
What the company does, where it operates, and who runs it.
About Polaryx Therapeutics, Inc. Common Stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alex Yang
- Headquarters
- South Tower, Paramus, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alex Yang
- Headquarters
- South Tower, Paramus, NJ, US
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions.
Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations.
And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Polaryx Therapeutics, Inc. Common Stock from FRC's valuation model, read against the market price. PLYX last traded at $1.88; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Polaryx Therapeutics, Inc. Common Stock. Starting points for Polaryx Therapeutics, Inc. Common Stock: EPS -$0.14, beta -8.28 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Polaryx Therapeutics, Inc. Common Stock. Polaryx Therapeutics, Inc. Common Stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Polaryx Therapeutics, Inc. Common Stock. Trailing twelve-month EPS for Polaryx Therapeutics, Inc. Common Stock stands at -$0.14. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$6.00
Median
$6.50
High
$7.00
Average target · 1 new target in the last 3 months, average $6.00
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.04 | -$0.05 | -$0.18 | -$0.28 |
| Low estimate | -$0.04 | -$0.05 | -$0.18 | -$0.29 |
| High estimate | -$0.04 | -$0.05 | -$0.18 | -$0.26 |
| No. of analysts | 3 | 3 | 3 | 3 |
| Year-ago EPS | — | -$0.03 | -$0.19 | — |
| Growth | — | -68.8% | +3.5% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Low estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| High estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| No. of analysts | 0 | 0 | 0 | 0 |
| Year-ago revenue | — | $0.00 | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 13, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Polaryx Therapeutics, Inc. Common Stock. Polaryx Therapeutics, Inc. Common Stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Polaryx Therapeutics, Inc. Common Stock valued side by side against its closest peers. Polaryx Therapeutics, Inc. Common Stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold Polaryx Therapeutics, Inc. Common Stock, and how their positions are changing. At a $93.7M market value, institutional positions materially move Polaryx Therapeutics, Inc. Common Stock's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Polaryx Therapeutics, Inc. Common Stock. Coverage tracks Polaryx Therapeutics, Inc. Common Stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Polaryx Therapeutics, Inc. Common Stock.